Literature DB >> 16553511

Minocycline for short-term neuroprotection.

Hazem F Elewa1, Hend Hilali, David C Hess, Livia S Machado, Susan C Fagan.   

Abstract

Minocycline is a widely used tetracycline antibiotic. For decades, it has been used to treat various gram-positive and gram-negative infections. Minocycline was recently shown to have neuroprotective properties in animal models of acute neurologic injury. As a neuroprotective agent, the drug appears more effective than other treatment options. In addition to its high penetration of the blood-brain barrier, minocycline is a safe compound commonly used to treat chronic infections. Its several mechanisms of action in neuroprotection -- antiinflammatory and antiapoptotic effects, and protease inhibition -- make it a desirable candidate as therapy for acute neurologic injury, such as ischemic stroke. Minocycline is ready for clinical trials of acute neurologic injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553511      PMCID: PMC3171989          DOI: 10.1592/phco.26.4.515

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  52 in total

Review 1.  Neuroprotection.

Authors:  K R Lees
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine.

Authors:  J R O'Dell; K W Blakely; J A Mallek; P J Eckhoff; R D Leff; S J Wees; K M Sems; A M Fernandez; W R Palmer; L W Klassen; G A Paulsen; C E Haire; G F Moore
Journal:  Arthritis Rheum       Date:  2001-10

Review 3.  Current status and perspectives of neuroprotection in ischemic stroke treatment.

Authors:  E Martínez-Vila; P I Sieira
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

4.  Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.

Authors:  T Tikka; B L Fiebich; G Goldsteins; R Keinanen; J Koistinaho
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

5.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.

Authors:  Y He; S Appel; W Le
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

Review 6.  Targeting the central nervous system inflammatory response in ischemic stroke.

Authors:  K J Becker
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

7.  Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage.

Authors:  Nobutaka Morimoto; Masamitsu Shimazawa; Tetsumori Yamashima; Hiroichi Nagai; Hideaki Hara
Journal:  Brain Res       Date:  2005-04-13       Impact factor: 3.252

8.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.

Authors:  J Yrjänheikki; T Tikka; R Keinänen; G Goldsteins; P H Chan; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 9.  Advances in the vascular pathophysiology of ischemic stroke.

Authors:  G J del Zoppo; J M Hallenbeck
Journal:  Thromb Res       Date:  2000-05-01       Impact factor: 3.944

10.  Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction.

Authors:  R O Sanchez Mejia; V O Ona; M Li; R M Friedlander
Journal:  Neurosurgery       Date:  2001-06       Impact factor: 4.654

View more
  56 in total

1.  Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice.

Authors:  Hu Chen; Hari Manev
Journal:  Neuropharmacology       Date:  2010-09-22       Impact factor: 5.250

Review 2.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

3.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

4.  Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke.

Authors:  Puja Garg; R Scott Duncan; Simon Kaja; Alexander Zabaneh; Kent D Chapman; Peter Koulen
Journal:  Neurosci Lett       Date:  2011-02-04       Impact factor: 3.046

5.  Cytokines reduce toxic effects of ethanol on oligodendroglia.

Authors:  Joyce A Benjamins; Liljana Nedelkoska; Robert P Lisak; John H Hannigan; Robert J Sokol
Journal:  Neurochem Res       Date:  2011-01-29       Impact factor: 3.996

6.  Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy.

Authors:  Ping Yan; Alec Zhu; Fan Liao; Qingli Xiao; Andrew Kraft; Ernie Gonzales; Ron Perez; Steven M Greenberg; David Holtzman; Jin-Moo Lee
Journal:  Stroke       Date:  2015-05-05       Impact factor: 7.914

Review 7.  rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines.

Authors:  Chinwe U Chukwudi
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

9.  Minocycline Attenuates High Mobility Group Box 1 Translocation, Microglial Activation, and Thalamic Neurodegeneration after Traumatic Brain Injury in Post-Natal Day 17 Rats.

Authors:  Dennis W Simon; Rajesh K Aneja; Henry Alexander; Michael J Bell; Hülya Bayır; Patrick M Kochanek; Robert S B Clark
Journal:  J Neurotrauma       Date:  2017-08-22       Impact factor: 5.269

Review 10.  Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Authors:  Kevin M Budge; Matthew L Neal; Jason R Richardson; Fayez F Safadi
Journal:  Mol Neurobiol       Date:  2017-08-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.